Dr. Erickson has worked to obtain continuous federal, foundation, internal, and industry funding supporting his and his collaborators' research over the last 10 ten years of his career. He is the inventor or co-inventor on many patents focused on translational treatment development in neurodevelopmental disorders that are held at Cincinnati Children's Hospital Medical Center and at his previous employer the Indiana University School of Medicine. He is considered an international expert in the clinical treatment of fragile X syndrome and has similar expertise in fragile X-specific clinical trial development. Dr. Erickson is additionally an avid teacher of future generations of child psychiatrists has received several teaching awards for his work in physician education. He also enjoys mentoring junior faculty in the behavioral and developmental neuropsychiatry sub-field of child psychiatry.

Specifically in research, he and his colleagues have moved forward several repurposed molecules for study in fragile X syndrome and autism spectrum disorder including work with acamprosate, riluzole, ketamine, D cycloserine, and N acetyl cysteine among other repurposed molecules. He also is working now to move several novel molecules into autism and fragile X-specific study using proprietary compounds abandoned from initially intended use that may hold promise in the disorders which he and his colleagues study.

MD: University of Cincinnati College of Medicine, Cincinnati, OH, 2003.

MS: Indiana University School of Medicine, Indianapolis, IN, 2008.

Residency and Fellowship: Indiana University School of Medicine, Indianapolis, IN, 2003-2008.

Certification: Child and Adolescent Psychiatry, 2009; Adult Psychiatry, 2008.


Fragile X syndrome; inpatient neurodevelopmental disorders acute crisis stabilization

Services and Specialties



Fragile X syndrome; autism spectrum disorders; neurodevelopmental disorders; molecular blood markers; quantitative measurement of pathophysiology in developmental disabilities; translational treatment development; psychiatric services for those with developmental disabilities and severe behavior

Research Areas


Insurance Information

Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.

View Insurance Information


Results of a phase Ib study of SB-121, an investigational probiotic formulation, a randomized controlled trial in participants with autism spectrum disorder. Schmitt, LM; Smith, EG; Pedapati, EV; Horn, PS; Will, M; Lamy, M; Barber, L; Trebley, J; Meyer, K; Heiman, M; et al. Scientific Reports. 2023; 13.

Behavioral inflexibility in fragile X syndrome: Accounts from caregivers and self-advocates. Jones, A; Kang, S; Shaffer, RC; Erickson, CA; Schmitt, LM. Frontiers in Psychology. 2023; 14.

Neuropsychiatric feature-based subgrouping reveals neural sensory processing spectrum in female FMR1 premutation carriers: A pilot study. Norris, JE; Schmitt, LM; De Stefano, LA; Pedapati, EV; Erickson, CA; Sweeney, JA; Ethridge, LE. Frontiers in Integrative Neuroscience. 2023; 17.

Editorial: Precision medicine approaches for heterogeneous conditions such as autism spectrum disorders (The need for a biomarker exploration phase in clinical trials - Phase 2m). Beversdorf, DQ; Anagnostou, E; Hardan, A; Wang, P; Erickson, CA; Frazier, TW; Veenstra-VanderWeele, J. Frontiers in Psychiatry. 2023; 13.

Parallel learning and cognitive flexibility impairments between Fmr1 knockout mice and individuals with fragile X syndrome. Schmitt, LM; Arzuaga, AL; Dapore, A; Duncan, J; Patel, M; Larson, JR; Erickson, CA; Sweeney, JA; Ragozzino, ME. Frontiers in Behavioral Neuroscience. 2023; 16.

Altered frontal connectivity as a mechanism for executive function deficits in fragile X syndrome. Schmitt, LM; Li, J; Liu, R; Horn, PS; Sweeney, JA; Erickson, CA; Pedapati, EV. Molecular Autism. 2022; 13.

Hemispheric Utilization of Alpha Oscillatory Dynamics as a Unique Biomarker of Neural Compensation in Females with Fragile X Syndrome. Norris, JE; Destefano, LA; Schmitt, LM; Pedapati, EV; Erickson, CA; Sweeney, JA; Ethridge, LE. ACS Chemical Neuroscience. 2022; 13:3389-3402.

Optimization, validation and initial clinical implications of a Luminex-based immunoassay for the quantification of Fragile X Protein from dried blood spots. Boggs, AE; Schmitt, LM; McLane, RD; Adayev, T; LaFauci, G; Horn, PS; Dominick, KC; Gross, C; Erickson, CA. Scientific Reports. 2022; 12.

Baclofen-associated neurophysiologic target engagement across species in fragile X syndrome. Jonak, CR; Pedapati, EV; Schmitt, LM; Assad, SA; Sandhu, MS; DeStefano, L; Ethridge, L; Razak, KA; Sweeney, JA; Binder, DK; et al. Journal of Neurodevelopmental Disorders. 2022; 14.

A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX). Berry-Kravis, E; Hagerman, R; Budimirovic, D; Erickson, C; Heussler, H; Tartaglia, N; Cohen, J; Tassone, F; Dobbins, T; Merikle, E; et al. Journal of Neurodevelopmental Disorders. 2022; 14.

Patient Ratings and Comments

All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey

Overall Patient Rating